4.1 Therapeutic indications
Cymevene is indicated in adults and adolescents ≥ 12 years of age for the:
- treatment of cytomegalovirus (CMV) disease in immunocompromised patients;
- prevention of CMV disease using pre-emptive therapy in patients with drug- induced immunosuppression (for example following organ transplantation or cancer chemotherapy).
Cymevene is also indicated from birth for the:
- prevention of CMV disease using universal prophylaxis in patients with drug- induced immunosuppression (for example following organ transplantation or cancer chemotherapy).
Consideration should be given to official guidance on the appropriate use of antiviral agents.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).